TABLE 4.
Clinical trial characteristics.
| No. subjects (range) | No. CTs (%) |
|---|---|
| ≤200 (60–200) | 10 (13.0) |
| 201–500 (206–500) | 25 (32.5) |
| 501–1,000 (530–1,000) | 13 (16.9) |
| 1,001–2,000 (1,100–2000) | 14 (18.2) |
| 2,001–10,000 (2,250–6,400) | 11 (14.3) |
| >10,000 (10,990–40,000) | 3 (3.9) |
| CT population | No. CTs (%) |
| HCW | 50 (64.9) |
| Contacts | 13 (16.9) |
| Vulnerable patients | 8 (10.4) |
| Other | 6 (7.8) |
| Maintenance dose | No. CTs (%) |
| 200 mg/day | 18 (23.4) |
| 400 mg/day | 18 (23.4) |
| 600 mg/day | 3 (3.9) |
| 400 mg/week | 18 (23.4) |
| Other | 21 (27.3) |
| Treatment duration (range) | No. CTs (%) |
| Max 5 days (4–5) | 9 (11.7) |
| Max14 days (10–14) | 6 (77.9) |
| Max 21 days (21) | 2 (2.6) |
| Max 30 days (28–30) | 5 (6.5) |
| Max 60 days (40–60) | 21 (27.3) |
| >60 days (77–180) | 20 (26.0) |
| Other/not reported (/) | 14 (18.2) |
CT, clinical trial; HCW, healthcare worker.